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High Patient Activation Is Associated With Remission in Patients 
With Inflammatory Bowel Disease
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Background: High levels of patient activation (having the knowledge, skills, and confidence to effectively manage one’s care), have been associ-
ated with improved outcomes in many chronic conditions. There have been few studies of the effects of activation in patients with inflammatory 
bowel disease (IBD). We performed a large, prospective Internet-based study to assess the relationship between patient activation level and clinical 
remission in patients with Crohn’s disease or ulcerative colitis.
Methods: We administered the Patient Activation Measure (Insignia Health) to 1486 cohort participants. Patients completed a follow-up survey 
within 13 months (median, 189 days). We collected demographic and clinical data; anxiety and depression were assessed using Patient-Reported 
Outcomes Measurement Information System instruments. We used bivariate analyses and multivariable logistic regression to identify character-
istics associated with low or high patient activation and to evaluate the association between levels of patient activation and subsequent disease 
activity.
Results: Higher anxiety (adjusted odds ratio [aOR], 0.32; 95% confidence interval [CI], 0.29–0.36) and depression (aOR, 0.33; 95% CI, 0.29–
0.37) scores were associated with a decreased odds of high patient activation. After we adjusted for education status, smoking, medication use, 
and other confounders, we found that patients with high activation at baseline were more likely to be in clinical remission during the follow-up 
period (aOR, 1.71; 95% CI, 1.20–2.45).
Conclusions: In a large, prospective Internet-based cohort of patients with IBD, we found a strong association between patient activation and 
clinical remission. These findings suggest that patient activation affects disease outcomes.
Key Words:  PAM, disease activity, clinical outcomes, psychologic factor
INTRODUCTION
As the care of patients with inflammatory bowel disease 
(IBD) has become more complex, it is even more important 
that providers engage patients in the decision-making process. 
Patient involvement in the management of IBD is particularly 
critical to improving treatment adherence,1–3 especially in the 
setting of an expanding array of medical and surgical treat-
ments for Crohn’s disease (CD) and ulcerative colitis (UC).
There is an increased interest in the concept of patient 
activation,4 which is defined by a patient’s demonstration of 
the skills, knowledge, and motivation needed to effectively 
manage one’s health and participate in health care decisions.5, 6 
In many chronic conditions, higher levels of patient activa-
tion have been linked to improvements in health outcomes,6, 7  
better patient experiences related to their health care,8 and 
lower overall health care costs.9, 10 In comparison, less acti-
vated patients demonstrate higher unmet medical needs and 
are significantly more likely to delay medical care.11 In prospec-
tive evaluations, increases in patient activation over time have 
been linked to significant improvements in health management 
behaviors such as regular exercise, stress management, and die-
tary modifications.12 In other populations, increasing patient 
activation through tailored interventions has been associated 
with improved adherence and decreased resource utilization 
such as hospitalizations.13, 14
Although patient activation has not been extensively 
investigated among patients with IBD, it is highly relevant 
given the strong desire of  patients to be involved in their care15, 
16 and an increased emphasis on shared decision-making.16 
Given the association between better health outcomes and 
higher levels of  patient activation in other chronic conditions, 
we hypothesized that patients with IBD demonstrating high 
patient activation at baseline would be more likely to dem-
onstrate clinical remission in follow-up evaluations when 
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compared with patients with low patient activation. We per-
formed a prospective cohort study utilizing the Crohn’s and 
Colitis Foundation’s IBD Partners Internet-based cohort to 
identify patient-specific and disease-related factors associated 
with high levels of  patient activation and to assess the relation-




We identified patients with a self-reported history of 
UC or CD within IBD Partners, an Internet-based cohort 
of patients with IBD. The study cohort has previously been 
described in detail.17–19 Since its initiation in 2011, >15,000 
patients with self-reported IBD have enrolled in the cohort. 
Members complete baseline and follow-up surveys (given at 
6-month intervals). Surveys include core questions with in-
formation on disease phenotype, activity, medication use,
and patient-reported outcomes (PROs), along with optional
“modules” to assess specific areas of interest among patients
with IBD. For this study, we invited consecutive patients who
completed an IBD Partners survey between June 2, 2016, and
January 5, 2017, to complete the 13-item survey of patient
activation known as the Patient Activation Measure (PAM;
Insignia Health)20 as an optional module.
Survey Instruments
Patient activation measure
Each of the 13 items in the PAM is followed by a 4-point 
Likert scale (Supplementary Table 1). The PAM assesses 4 lev-
els of activation: (1) the patient is disengaged and overwhelmed, 
(2) the patient is becoming aware but still struggling, (3) the pa-
tient takes action, and (4) the patient maintains behaviors. In
the creation of the original PAM, Rasch analysis was used to
select an initial set of items for inclusion,5 which allows for the
creation of unidimensional scales from ordinal data, in addition 
to calibrating the difficulty of an item as related to response
probabilities. Once a measure has been created, individuals can
then be assessed in relation to a particular scale. When evalu-
ating the PAM, a respondent’s location on the scale indicates
how activated the patient is.5 The psychometric properties of
the PAM have been assessed in multiple health care settings.21–23
Based on varying levels of agreement or disagreement to the 13
statements included in the PAM, scores were transformed from
the initial patient response scale to a continuous (0–100) scale,
where higher scores represent higher levels of patient activa-
tion.5, 20 Using prespecified threshold values,10, 20 patients were
grouped into the 4 levels of activation. For our analyses, high
patient activation was defined as level 3 or level 4 activation.10, 24
We also performed sensitivity analyses comparing those
patients with level 4 activation (the highest activation) with all 
other patients surveyed.
Clinical remission
Clinical remission was defined as a short Crohn’s Disease 
Activity Index (sCDAI)25 score ≤150 for subjects with CD or a 
Simple Clinical Colitis Activity Index (SCCAI)26 score ≤2 for 
subjects with UC.
Study Variables
In addition to the PAM and disease activity measures, 
other demographic and clinical factors were collected, 
including age, sex, years since IBD diagnosis, history of 
IBD-related surgery, maximum education level attained, and 
tobacco use. Anxiety and depression were assessed using 
Patient-Reported Outcomes Measurement Information 
System (PROMIS) instruments. Developed by the National 
Institutes of  Health, PROMIS instruments are general 
measures, not specific to IBD, that have been previously 
described in the IBD Partners population.27 These measures 
are calibrated using a T-score metric, with the mean of  the 




Continuous variables were summarized using means 
and SDs and compared using the Student t test and Wilcoxon 
rank-sum test as appropriate. Categorical variables were 
expressed as proportions and compared using Fisher exact and 
chi-square testing. Bivariate and multivariable logistic regres-
sion models were utilized to evaluate the clinical and demo-
graphic characteristics that were associated with high (level 3 
or level 4) patient activation. In creating the odds ratios (ORs) 
for anxiety and depression, ORs were transformed to indicate 
the odds of  an increase in anxiety or depression 1 SD from 
the mean T score. The decision to include covariates in the 
final multivariable models was made a priori, based on prior 
associations with patient activation or the clinical course of 
patients with IBD.
Prospective analysis
We used similar bivariate techniques as those described 
above to evaluate the relationship between patient activation 
and clinical remission during the follow-up period. Additionally, 
we used multivariable logistic regression to control for potential 
confounders when evaluating the relationship between patient 
activation and clinical remission. All covariates included in the 
multivariable analysis were identified a priori based on prior 
association with patient activation or clinical disease activity 
in IBD. We intentionally did not include anxiety or depression 
in the analyses of patient activation and disease activity in the 
follow-up period. This decision was based on prior evaluations 
that have demonstrated an association between anxiety and de-
pression and disease activity in the IBD Partners population28, 29 
and prior demonstrations of a significant relationship between 
patient activation and depression.30 We believe that the rela-
tionship between anxiety and depression and clinical remission 
may be in part mediated by patient activation (and thus patient 
activation may be on the causal pathway between anxiety/de-
pression and disease activity). In addition, we made the inten-
tional decision not to adjust for baseline disease activity based 
on prior literature suggesting the potential bias in adjusting for 
baseline disease status when performing evaluations such as 
disease activity over time.31
All statistical analyses were performed using SAS (ver-
sion 9.4) statistical software (SAS Institute, Cary, NC, USA). 
The study protocol was approved by the Institutional Review 
Board at the University of North Carolina at Chapel Hill.
RESULTS
Study Population
The study population included 1486 total participants 
(976 with CD [66%] and 510 with UC [34%]) from all 50 states 
and Puerto Rico, along with 84 patients from other countries. 
Overall, the response rate to the PAM module was 84%. There 
were no demographic or clinical differences among those who 
declined to participate when compared with the responders. The 
full demographic and clinical characteristics of patients com-
pleting the PAM module are presented in Table 1. The mean 
age of participants (SD) was 43.8 (15.2) years; 74% were fe-
male. Of the 1486 total participants, 77% reported their highest 
level of education as college or graduate school. The mean dis-
ease duration (SD) was 14.4 (12.6) years, with 43% of patients 
with CD reporting a history of CD-related surgery.
Predictors of High Patient Activation
Overall, 1259 (85%) respondents demonstrated high lev-
els of patient activation, defined as level 3 or 4 activation. In the 
unadjusted analysis, patients with a history of IBD-related surgery 
demonstrated an increased odds of high patient activation (OR, 
1.48; 95% confidence interval [CI], 1.07–2.05), whereas nonwhite 
patients (OR, 0.57; 95% CI, 0.33–0.97), and those reporting cur-
rent smoking (OR, 0.40; 95% CI, 0.21–0.78) had a decreased odds 
of high patient activation; however, these results were not signif-
icant in multivariable analysis (Table 2). In both unadjusted and 
multivariable analysis adjusting for confounders, patients with 
higher anxiety (adjusted OR [aOR], 0.40; 95% CI, 0.34–0.46) and 
higher depression scores (aOR, 0.40; 95% CI, 0.34–0.46) demon-
strated a decreased odds of high patient activation. Patients with 
longer disease duration demonstrated an increased odds of high 
patient activation (aOR, 1.42; 95% CI, 1.02–1.97).
Patient Activation and Remission
Of the 1486 participants who completed the PAM module, 
1082 (73%) completed a follow-up survey within 13 months of 
their baseline survey (median interval [interquartile range], 
189 [183–209] days). Those patients who did not complete a 
follow-up survey were less likely to demonstrate high patient 
activation at baseline (81% vs 86%; P = 0.008). The other dem-
ographic and clinical comparisons of these groups are depicted 
in Supplementary Table 2.
In the evaluation of the relationship between patient 
activation level and remission, patients with high activation at 
baseline were significantly more likely to demonstrate clinical 
remission at the follow-up assessment (65% vs 51%; P = 0.002, 
Figure  1). When analyzed with multivariable analysis, high 
patient activation at baseline was associated with clinical remis-
sion at follow-up after adjusting for potential confounders 
(aOR, 1.71; 95% CI, 1.20–2.45, Table 3). In a sensitivity anal-
ysis comparing patients with level 4 activation with all others, 
the relationship between high patient activation at baseline 
and clinical remission at follow-up was also demonstrated 
after adjusting for potential confounders (aOR, 1.74; 95% CI, 
1.34–2.25) (Supplementary Table 3).
DISCUSSION
In a prospective analysis using a large, geographically 
diverse cohort of patients with IBD, we prospectively demon-
strated that patients scoring in the highest levels of patient activa-
tion were more likely to be in clinical remission during subsequent 
surveys. This demonstrates a potential role for patient activation 
in the disease course of patients with IBD and suggests the need 
for efforts to design and test interventions to improve patient 
activation in this population. Additionally, in a cross-sectional 
analysis, we identified a positive association between patient acti-
vation and time since diagnosis and inverse relationships between 
patient activation and anxiety and depression.
In a prior cross-sectional study that utilized the PAM to 
evaluate patient activation among IBD patients in the Veterans 
Affairs system, Munson et al.32 demonstrated strong correlations 
between patient activation and health-related quality of life. Our 
results expand upon this earlier study in a number of ways. First, 
the demographics of our cohort were quite different than in this VA 
population, which was 90% male with a median age of 63 years.32 
Additionally, our study utilized a prospective design and evaluated 
outcomes of patient-reported disease activity/remission.
In a cross-sectional study of more than 25,000 patients 
presenting for primary care visits, Greene and Hibbard demon-
strated an association between higher patient activation and a 
variety of health-related outcomes including improved blood 
pressure control and follow-up with recommended preventive 
screening.7 Although the rates of smoking were higher than 
those reported in our population, Greene and Hibbard7 also 
demonstrated a stark decrease in rates of smoking moving 
TABLE 1. Comparison of Demographics and Clinical Characteristics Among Patients From IBD Partners Comparing 







Ulcerative colitis, No. % 75 33 435 35
Age, mean (SD), y 43.4 (15.5) 43.9 (15.2)
Female sex, No. % 169 74 928 74
Race, No. %
 White 208 91 1197 95
African American 4 2 14 1
 Asian 4 2 11 1
More than 1 race 5 2 26 2
 Other 6 3 11 1
US Census Bureau Region, No. %
 Northeast 19 18 86 82
 Midwest 43 14 268 86
 South 57 15 328 85
 West 56 12 394 88
Age at IBD diagnosis, mean (SD), y 30.9 (13.7) 29.2 (13.4)
Time since IBD diagnosis, mean (SD), y 12.5 (12.2) 14.7 (12.6)
Education, No. %
<12th grade 5 2 7 1
12th grade 14 6 68 5
Attended college, did not graduate 48 21 200 16
Graduated from college 88 39 546 44
Graduate school 72 32 438 35
Current smoker, No. % 15 7 38 3
Saw a gastroenterologist in the past year, No. %
 Never 16 8 75 6
1–2 times 106 50 654 55
3–4 times 61 29 318 27
≥5 times 28 13 134 11
Saw a primary care provider in the past year, No. %
 Never 14 7 88 8
1–2 times 97 49 675 60
3–4 times 57 29 274 24
≥5 times 30 15 94 8
History of Crohn’s disease–related surgery,a No. % 73 13 492 60
Hospitalized for IBD in the past year, No. % 23 11 107 9
Medication use at initial assessment, No. %
No medications 51 22 289 23
Combination therapy with a biologic and an immunomodulator 31 14 204 16
Biologic therapy 74 33 370 29
 Immunomodulator 32 14 154 12
 Aminosalicylate 39 17 242 19
Clinical remission at initial assessment, No. % 88 43 725 65
High anxiety at baseline,b No. % 67 30 133 11
High depression at baseline,b No. % 80 35 174 14
aHistory of surgery only assessed among patients with Crohn’s disease.
bAnxiety and depression were assessed by PROMIS measures; high anxiety or depression were defined as 1 SD from the mean.
from level 1 of patient activation to level 4.  In several other 
chronic disease states such as multiple sclerosis33 and HIV,34 
higher patient activation scores have been associated with 
better health-related outcomes such as increased adherence and 
higher CD4 counts. Perhaps most concerning for patients with 
chronic, potentially debilitating diseases such as UC and CD, 
less activated patients are more likely to delay medical care.11
We have shown that IBD patients with high activation 
are more likely to achieve remission. Patients with IBD and 
high activation may be more adherent to therapies or may be 
more proactive in engaging in healthy behaviors such as exer-
cise,35 all of which could lead to increased rates of remission. 
Prospective interventional studies to evaluate the effectiveness 
of different strategies to improve patient activation are needed. 
Several prior studies in non-IBD populations have evaluated 
interventions for improving patient activation, including peer 
support groups36, 37 and tailored coaching13, 14 approaches aimed 
at increasing self-management techniques. In 1 randomized 
study of patients with heart failure, patients in the intervention 
group underwent a 6-month program aimed at increasing pa-
tient activation and self-management behaviors. These patients 
demonstrated significant increases in patient activation, along 
with improvements in medication adherence and lower rates of 
hospitalization when compared with the standard care group.13
Similar efforts to improve patient activation, where tar-
geted goals are tailored to an individual’s activation level,14 
have the potential to significantly impact the management of 
patients with IBD. Targeting interventions at an individual’s 
activation level allows a patient to build a sense of confidence, 
increasing the ultimate likelihood of successful intervention. 
For example, at the lowest level of activation (level 1), interven-
tions might focus on building self-awareness of how behaviors 
might impact the disease course of CD or UC. At the highest 
level of activation (level 4), interventions could be focused on 
handling new challenges or stresses in the management of CD 
and UC as they arise, in an effort to prevent disease relapse.14 
Finally, targeting specific populations for interventions may 
also prove beneficial. In addition to evaluating patient activa-
tion, larger-scale programs screening for anxiety and depression 
among patients with IBD could identify patients with psychiat-
ric comorbidities. Targeting patients with both low activation 
and psychiatric comorbidities may allow for the use of con-
comitant interventions to improve activation and anxiety and 
depression, which may ultimately improve clinical outcomes.
Given the association of decreased health care utilization 
among patients with high patient activation,6, 7, 9 efforts to iden-
tify patients with low patient activation who may be at increased 
risk of disease relapse may allow for such tailored interventions. 
Additionally, as treatment paradigms shift toward more shared 
decision-making processes,16 increasing patient activation 
could represent 1 strategy to improve communication between 
patients and providers. Although there have been few published 
studies regarding patient activation among patients with IBD 
thus far, most patients with IBD express a desire to be involved 
in the decision-making process15 and thus would likely welcome 
an opportunity for increased engagement with their provider.
When evaluating predictors of high patient activation, 
patients with a prior history of IBD-related surgery were more 
likely to demonstrate high patient activation in the unadjusted 
analysis. Prior surgery may be a marker of more severe disease, 
and thus the increase in activation may be a focused response 
to preceding events. We also demonstrated a decreased odds of 
having high patient activation among patients of nonwhite race 
in the unadjusted analysis. We are likely underpowered to fully 
evaluate this relationship given the small population of non-
white patients in IBD Partners. Additionally, although we did 
not assess health literacy, in prior evaluations of internal med-
icine and geriatric populations, the relationship between race 
TABLE  2. Odds of High Patient Activation Among 






Female sex 0.93 (0.66–1.32) 1.28 (0.89–1.83)
Race
 White Reference Reference
 Nonwhite 0.57 (0.33–0.97) 0.82 (0.44–1.55)
Education
12th grade or less 0.94 (0.50–1.76) 1.22 (0.61–2.45)
Attended college, did not 
graduate
Reference Reference
Graduated from college 1.46 (0.97–2.19) 1.13 (0.73–1.76)
 Graduate school 1.38 (0.91–2.09) 0.99 (0.63–1.56)
Time since diagnosis, y
 ≤10 Reference Reference
>10 1.66 (1.21–2.26) 1.42 (1.02–1.97)
Current smoker 0.40 (0.21–0.78) 0.68 (0.33–1.42)
History of IBD-related 
surgery
1.48 (1.07–2.05) 1.42 (0.98–2.04)
Medication use at initial 
assessment
No medications 1.20 (0.72–1.99) 1.45 (0.84–2.49)
Combination therapy 1.41 (0.81–2.44) 1.71 (0.95–3.08)
 Biologic 1.06 (0.67–1.69) 1.08 (0.66–1.77)
 Immunomodulator Reference Reference
 Aminosalicylate 1.28 (0.76–2.14) 1.29 (0.75–2.24)
Anxietyb 0.32 (0.29–0.36) 0.32 (0.29–0.36)
Depressionb 0.32 (0.29–0.36) 0.33 (0.29–0.37)
Ulcerative colitis 1.05 (0.77–1.44) 1.25 (0.87–1.80)
aAll variables listed above were included in the final multivariable analysis.
bAnxiety and depression were assessed by PROMIS measures; odds ratios depicted 
above indicate odds associated with an increase in anxiety or depression 1 SD from 
the mean T score.
and patient activation was significantly mediated by education 
and health literacy.38, 39
Our study was large, including a cohort of  patients with 
self-reported UC or CD and careful methodology that has been 
utilized in numerous other studies within IBD Partners.17–19, 
28, 29 However, our study also has limitations. Given that the 
IBD Partners cohort is a voluntary Internet-based cohort, 
participants may exhibit higher levels of  patient activation 
than the general IBD population, which may limit the gen-
eralizability of  our findings. Despite the relatively selected 
population of  the IBD Partners cohort, including a large 
number of  college graduates, prior studies of  IBD Partners 
participants have replicated the findings of  these studies using 
other methods.28, 29 Although the population represented all 
regions of  the United States, we did not have access to other 
geographic or socioeconomic factors that may also influence 
patient activation such as urban or rural location, household 
income,40 or employment status. To evaluate patient activation 
and clinical remission in this population, we used validated 
survey instruments that have been utilized previously in IBD 
Partners.19, 25, 26, 28, 29 However, we did not have more objective 
evidence of  clinical remission in this study, such as laboratory 
or endoscopic data. Although the majority of  participants 
completed follow-up 6  months after the initial PAM assess-
ment, there was some heterogeneity present in the interval be-
tween responses. We did have a loss of  27% of  patients in the 
prospective evaluation, and these participants demonstrated 
lower patient activation at baseline compared with those par-
ticipants who completed follow-up assessments. Given that 
high patient activation was associated with an increased odds 
of  remission, the overall demonstration of  significant findings 
TABLE  3. Odds of Remission at Follow-up Survey 
Among Participants in IBD Partners, Unadjusted and 






Low patient activation Reference Reference
 High patient activation 1.74 (1.23–2.46) 1.71 (1.20–2.45)
Female sex 0.84 (0.63–1.11) 0.83 (0.62–1.10)
Race
 White Reference Reference
 Nonwhite 0.74 (0.42–1.31) 0.73 (0.41–1.30)
Education
12th grade or less 0.86 (0.48–1.53) 0.84 (0.47–1.51)
Attended college, did 
not graduate
Reference Reference
Graduated from college 1.19 (0.84–1.71) 1.17 (0.81–1.68)
 Graduate school 1.42 (0.98–2.04) 1.38 (0.95–2.01)
Time since diagnosis, y
 ≤10 Reference Reference
>10 0.97 (0.76–1.24) 0.96 (0.69–1.34)
Current smoker 0.62 (0.31–1.23) 0.75 (0.31–1.79)
Medication use at initial 
assessment
No medications 0.60 (0.39–0.94) 0.60 (0.38–0.95)
Combination therapy 0.66 (0.42–1.06) 0.64 (0.40–1.02)
 Biologic 0.73 (0.48–1.12) 0.74 (0.48–1.13)
 Immunomodulator Reference Reference
 Aminosalicylate 0.74 (0.47–1.15) 0.71 (0.45–1.13)
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FIGURE 1. The percentage of patients in remission at follow-up, comparing patients with high activation with patients with low activation.
despite the lack of  follow-up among this set of  patients would 
seem to strengthen our findings.
In conclusion, using a large cohort of patients with IBD, 
we found that patients with high activation at baseline were 
more likely to be in remission during follow-up assessments. 
Patient activation is a relatively novel concept in IBD, and these 
findings suggest that patient activation may play an important 
role in disease outcomes. As this is a modifiable factor, screening 
for patient activation, coupled with appropriate interventions 
to improve patient activation among those patients with low 
activation levels, could improve care and ultimately improve 
outcomes among patients with IBD.
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
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